Share this article
Share this article
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Award winning market research company has published a report on the global respiratory virus vaccines market. As per the study, R&D on respiratory vaccines is focused on COVID-19 at the moment, however, the long-term outlook remains positive. Learning from the impact of COVID-19, governments around the globe are focusing on developing adequate treatment options for respiratory vaccines.
With over 110 million active cases globally, pharmaceutical companies are racing against time to introduce potential vaccine candidates. Breakthroughs have manifested themselves in the form of three final products: the Pfizer-BioNTech COVID-19 vaccine, COVAXIN